Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer

NCT00818961 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

36

Enrollment

OTHER

Sponsor class

Stopped terminated early due to meeting end point with fewer patients than anticipated

Conditions

Leukemia
Lymphoma
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Diseases

Interventions

BIOLOGICAL: alemtuzumab
BIOLOGICAL: graft-versus-tumor induction therapy
BIOLOGICAL: rituximab
DRUG: busulfan
DRUG: cyclophosphamide
DRUG: fludarabine phosphate
DRUG: methotrexate
DRUG: tacrolimus
PROCEDURE: allogeneic bone marrow transplantation

Sponsor

Northside Hospital, Inc.

Collaborators

[object Object]